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Abstract
Background:  The number of leishmaniasis cases associated with immunosuppression has
increased regularly over the past 20 years. Immunosuppression related to HIV infection,
immunosuppressive treatment, organ transplantation, and neoplastic diseases increases the risk for
Leishmania-infected people to develop visceral illness.
Case presentation: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-
treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for
asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with
myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
Conclusion:  Physicians should recognise CS-treated patients as a population likely to be
immunesuppressed. In immunodeficiency conditions, unusual forms of leishmaniasis can develop
and foster the risk of a diagnostic delay and of poor response to therapy.
Background
The number of leishmaniasis cases associated with immu-
nosuppression has increased regularly over the past 20
years. Immunosuppression related to HIV infection,
drugs, organ transplantation, and neoplastic diseases
increases the risk for Leishmania-infected people to
develop visceral illness. In southwestern Europe visceral
leishmaniasis (VL) is the clinical form most frequently
associated to immunosuppression, particularly to HIV
infection [1,2]. In immunodeficiency conditions, unusual
forms of leishmaniasis can develop and foster the risk of
a fatal diagnostic delay and of a poor response to therapy.
Case presentation
Patient 1
In August 2001, a 79-year-old man was admitted to a
community hospital because of a violaceous, thickened,
dyskeratosic and painless lesion (diameter 2 × 2 cm) on
his tongue with a deep central ulcer. A biopsy of the lesion
showed deep inflammatory infiltration with macrophages
containing numerous Leishmania amastigotes.
The patient, a farmer living in the rural area around Rome
(Italy), was referred to our Institute. He had a glucose-6-
phosphate dehydrogenase deficiency, suffered from
asthma, and was given chronic corticosteroid (CS) ther-
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apy. The laboratory data on admission are reported in
Table 1. Protein electrophoresis showed a mild hypergam-
maglobulinaemia. The immunofluorescence assay (Dia-
medix Corporation®, Miami-Florida) for the detection of
anti-Leishmania infantum antibodies was positive (1:640).
The search for antibodies against HIV resulted negative. A
bone marrow aspirate did not show Leishmania amastig-
otes and a restriction fragment lenght polymorphism
polymerase chain reaction (PCR-RFLP) [3] for the search
of Leishmania DNA on bone marrow and peripheral blood
resulted negative. L. infantum was identified by PCR-RFLP
on the tongue biopsy.
The patient was treated with liposomal amphotericin B (3
mg/kg daily i.v. on days 1–5, 14 and 21) with complete
recovery. After a 3-year follow-up, no relapse was noted.
Patient 2
In February 2004, a 72-year-old housewife complained of
weight loss, recurrent fever, and diarrhea after pneumo-
nia. She lived in the rural area around Rome (Italy) and
had been taking CS and myorelaxants for 16 years because
of myasthenia gravis. In the year 2000, the patient was
treated for visceral leishmaniasis with bone marrow
involvement. A course of liposomal amphotericin B (1
mg/kg daily for 10 days) was repeated one year later for a
relapse with involvement of bone marrow and duode-
num: a clinical remission of fever and diarrhea was
obtained.
On admission to our Institute, the patient was taking
prednisone 25 mg daily and pyridostigmine 60 mg four
times daily. She was febrile (38.5°C) with an impaired
nutritional status (35 Kg) and a severe muscular hypotro-
phy. Upon examination, a first trigeminal branch herpes
zoster, and mild hepatomegaly were found; the left nostril
presented a cutaneous squamous and crusty lesion that
had appeared 4 months earlier.
The results of hematochemical assays are shown in table
1; particularly, a severe lymphopenia (lymphocytes 538/
mm3) with 215 CD4+ lymphocytes/mm3 and 132 CD8+/
mm3 was found. HIV antibody test was negative. The chest
X-rays showed an evolution from a single right basal con-
solidation to multiple bilateral pneumonic foci. The anti-
Leishmania infantum serologic titer was 1:640 and the
bone marrow biopsy showed numerous amastigotes of
Leishmania spp. Intra-macrophagic amastigotes were also
seen at histologic examination of the nasal lesion. L.
infantum was identified by PCR-RFLP on peripheral blood
and on nasal lesions. The patient was treated with lipo-
somal amphotericin B (3 mg/kg daily for 10 days, total 30
mg/kg), and with levofloxacin (500 mg daily for 10 days),
obtaining clinical remission with a gradual improvement
of the nasal lesion. No relapse was reported during a 9-
month follow-up.
Patient 3
A 54-year-old male, a farmer living in the rural area
around Grosseto, Tuscany (Italy), was admitted to our
Institute in March 2004 with a relapse of visceral and
mucocutaneous leishmaniasis. In 1997 he complained of
edema of the lips with maculopapular, non-itching
lesions: a Miescher's granulomatous cheilitis was diag-
nosed and he was treated with local and systemic CS
courses. The lesions of the perioral region disappeared,
unlike the lips edema. In April 2003, he was admitted to
a community hospital with remittent fever (40°C) associ-
ated to increasing asthenia and normocytic anemia.
Amastigotes of Leishmania were recognized in the bone
marrow and lip biopsies. The patient was treated with
liposomal amphotericin B (3 mg/kg daily i.v. on days 1–
5, 14 and 21, total 21 mg/kg). The fever disappeared and
Table 1: Laboratory values on admission
Patient 1 Patient 2 Patient 3 Normal value
Hemoglobin (g/dL) 12.70 9.60 10 12–18
White-cell count (per mm3) 6000 16800 6000 4.3–10.8
Neutrophils (%) 63.30 93.80 66.60 40–75
Lymphocytes (%) 26.50 3.20 18.50 20–51
Erythrocyte sedimentation rate (mm/h) 35 90 65 <20
CD4 cell count (per mm3) 502 215 661 500–1200
Platelet count (per mm3) 227000 386000 514000 200000–400000
Creatinine (mg/dL) 0.7 0.12 1.78 0.5–1.4
Protein (g/dl) 7 4.9 6.6 6.2–8.2
Albumin (%) 57.7 50.3 56.4 52–65
Gamma globulin (%) 20.8 12 16.4 10–19
Aspartate aminotransferase (U/L) 20 14 21 <40
Alanine aminotransferase (U/L) 14 25 18 <40
Alkaline phosphatase (U/L) 59 91 322 <65
Lactate dehydrogenase (mU/mL) 360 244 458 266–500BMC Infectious Diseases 2006, 6:177 http://www.biomedcentral.com/1471-2334/6/177
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the edema of the lips substantially decreased. However,
few weeks after the end of the therapy febrile episodes
recurred, and in December 2003 a new course of ampho-
tericin B therapy was prescribed (liposomal amphotericin
B, 5 mg/kg daily i.v. for 10 days). Clinical improvement
with persistent detection of L. infantum PCR-RFLP on
peripheral blood was observed.
On admission to our Institute the patient was febrile
(39°C) and presented lips edema with erythematous and
cutaneous squamous lesions, diffuse lymphadenopathy
and hepatosplenomegaly. The results of blood tests are
shown in the table 1. The patient experienced a progres-
sive reduction of hemoglobin (8.5 g/dL) and received two
whole blood transfusions. Multiple blood cultures, HIV
and Parvo virus B19 antibody searches were all negative.
The anti-Leishmania infantum antibodies were positive
(1:640), while the PCR-RFLP on peripheral blood resulted
negative. The patient was treated with two subsequent 28-
day courses of meglumine antimonate (20 mg/kg daily):
he experienced a rapid clinical improvement and no
adverse reactions. After a 6-month follow-up the patient is
still in good condition, although a modest lip edema still
remains. The antibody titer for Leishmania infantum is
1:160. The PCR for Leishmania spp. on peripheral blood is
negative. The bone marrow biopsy shows no evidence of
infection.
Conclusion
Visceral leishmaniasis is a potentially fatal infection in
immunocompromised hosts and current therapies fre-
quently fail to eradicate L. donovani from infected tissue
[4]. The clinical outcome is determined by the Th1
immune response, inducing the production of IFN-γ and
IL-2 in response to leishmanial antigens [5,6].
Glucocorticoids affect the effector, suppressor, and cyto-
toxic T cells functions trough the blockade of cytokine
expression [7], with the result of an increased susceptibil-
ity to infections, particularly with intracellular microbes
[8] such as occurs with Leishmania species. In a murine
model the prolonged use of steroids has been associated
to a decreased production of IL-2, IFN-gamma, IL-4 and
TNF-alfa and to a significant 3-fold increase in amastigote
burden in the spleen [9].
We have presented 3 cases of CS-treated patients with
diagnosis of Leishmania infantum leishmaniasis that posed
serious clinical dilemmas in terms of diagnostic delay and
partial response to therapy. Our three patients lived in
rural areas of central Italy (Latium and Tuscany regions)
where both visceral and cutaneous leishmaniasis are
endemic. In the past 7 years, some 200 cases of visceral
leishmaniasis were recorded from these regions, and in
most of the patients parasites have been identified as L.
infantum by means of isoenzyme analysis (unpublished
data from Istituto Superiore di Sanità, Rome). Our first
case is a paradigmatic description of the classical lip leish-
maniasis that occurred over centuries in Southern Europe.
The finding of a viscerotropic Leishmania as cause of a
localized leishmaniasis poses the question whether the
lesions observed may represent the site of the parasite
inoculation or a secondary localization [10]. The absence
of clinical, immunological and parasitological evidence of
generalized parasite dissemination in the first case
strongly supports the former hypothesis rather than sec-
ondary spread from an initial unknown source. Neverthe-
less the use of steroids and the elderly age of the patient
could suggest a secondary involvement of the tongue [10].
The prolonged incubation period already described in few
muco-cutaneous leishmaniasis cases [11,12] could sug-
gest as primary option the endogenous reactivation of the
infectious process promoted by the CS-induced impair-
ment of the immune response. Particularly, a laryngeal
leishmaniasis case has been described in a UK patient
undergoing inhalation and oral steroid therapy for
asthma who frequently visited Southern Europe without
extra European travels [11].
In the further two cases the prolonged steroid use was
likely to be associated to the clinical severity of the disease
[13,14]. In the female patient affected by myasthenia, the
relapses, the clinical spread to the gastrointestinal tract,
and the severe T lymphocyte defects were all factors likely
to be related to the sustained impairment of the immune
response. The third case shows the visceral involvement of
a leishmaniasis case initially confined to the skin region
only. The cutaneous leishmaniasis must be differentiated
from sporotrichosis, mycobacteriosis, sarcoidosis, syphi-
lis, lupus vulgaris, and neoplasms: in general, the histologic
examination led to the correct diagnosis. The peri-oral
lesions shared characteristics similar to those of the post-
kala-azar dermal leishmaniasis (PKDL) [15]. In our case,
the diagnosis of PKDL was excluded by the finding of par-
asites in the bone marrow.
The need of an early clinical advice of the leishmanias
diagnosis during the evaluation of HIV febrile patients liv-
ing in an endemic area is well-known. Nevertheless, unu-
sual presentations of leishmaniasis have to be suspected
as differential diagnosis in patients with immunosuppres-
sive conditions, other than HIV infection. We therefore
suggest a careful clinical evaluation of immune sup-
pressed patients resident in areas at risk for Leishmania
such as the coasts of the Mediterranean Basin. In such
patients the occurrence of lymphopenia, anemia, pancy-
topenia or hypergammaglobulinemia with recurrent
febrile episodes or of long-lasting painless ulcerative
lesions should alert clinicians to include leishmaniasis in
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